Bruce Cree, AAN 2022: Bruton tyrosine kinase inhibitors in multiple sclerosis – Key clinical highlights

Prof. Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the potential use of bruton tyrosine kinase inhibitors (BTKis) in the treatment of multiple sclerosis. Prof. Cree discusses BTKis novel mechanism of action and the rationale behind the investigation of this new class of drugs.

Question: What are the key clinical highlights in the treatment of multiple sclerosis?

View more content from Prof. Bruce Cree:

Bruce Cree, AAN 2022: Ublituximab and its potential use in the treatment of relapsing multiple sclerosis

Bruce Cree, AAN 2022: Disability improvements with ublituximab in relapsing multiple sclerosis – Phase 3 ULTIMATE I and II

Disclosures: Bruce Cree is a consultant for Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Gossamer Bio, Horizon, Neuron23, Novartis, Sanofi, TG Therapeutics and Therini; and receives grant/research support from Genentech; and is also on the advisory board for Autobahn.

Support:  Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022